Sökresultat - "cemiplimab"

Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study.

Haigh, Joseph Edward¹ (AUTHOR), Rack, Sam^1,2 (AUTHOR), Yan, Ruiyang^1,2,3 (AUTHOR), Babu, Sherin^1,4 (AUTHOR), Donnelly, Olly^3,4,5 (AUTHOR), Walter, Harriet⁵ (AUTHOR), Faust, Guy⁵ (AUTHOR), Bhagani, Shradha⁵ (AUTHOR), Isola, Patrick³ (AUTHOR), Metcalf, Robert¹ (AUTHOR) robert.metcalf1@nhs.net

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.

Baranda, Joaquina C.¹ (AUTHOR) jbaranda@kumc.edu, Robbrecht, Debbie² (AUTHOR), Sullivan, Ryan³ (AUTHOR), Doger, Bernard⁴ (AUTHOR), Santoro, Armando^5,6 (AUTHOR), Barve, Minal⁷ (AUTHOR), Grob, Jean‐Jacques⁸ (AUTHOR), Bechter, Oliver⁹ (AUTHOR), Vieito, Maria¹⁰ (AUTHOR), de Miguel, Maria Jose¹¹ (AUTHOR), Schadendorf, Dirk¹² (AUTHOR), Johnson, Melissa¹³ (AUTHOR), Pouzin, Clemence¹⁴ (AUTHOR), Cantalloube, Cathy¹⁴ (AUTHOR), Wang, Rui¹⁵ (AUTHOR), Lee, Jooyun¹⁶ (AUTHOR), Chen, Xiaofei¹⁶ (AUTHOR), Demers, Brigitte¹⁷ (AUTHOR), Amrate, Amele¹⁷ (AUTHOR), Abbadessa, Giovanni¹⁶ (AUTHOR)

Cemiplimab for metastatic squamous cell carcinoma of the orbit, periocular adnexa, and thigh.

Dhillon, Jobanpreet¹ (AUTHOR), Li, Daniel Q.² (AUTHOR), Burnier, Miguel² (AUTHOR), Shenouda, George³ (AUTHOR), Arthurs, Bryan P.² (AUTHOR), El-Hadad, Christian² (AUTHOR) christian.haddad@mcgill.ca

Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%.

Kilickap, Saadettin¹ (AUTHOR) skilickap@yahoo.com, Özgüroğlu, Mustafa² (AUTHOR), Sezer, Ahmet³ (AUTHOR), Gümüş, Mahmut⁴ (AUTHOR), Bondarenko, Igor⁵ (AUTHOR), Gogishvili, Miranda⁶ (AUTHOR), Turk, Haci M.⁷ (AUTHOR), Cicin, Irfan⁸ (AUTHOR), Bentsion, Dmitry⁹ (AUTHOR), Gladkov, Oleg¹⁰ (AUTHOR), Sriuranpong, Virote¹¹ (AUTHOR), Quek, Ruben G. W.¹² (AUTHOR), McIntyre, Debra A. G.¹² (AUTHOR), He, Xuanyao¹² (AUTHOR), McGinniss, Jennifer¹² (AUTHOR), Seebach, Frank¹² (AUTHOR), Gullo, Giuseppe¹² (AUTHOR), Rietschel, Petra¹² (AUTHOR), Pouliot, Jean‐Francois¹² (AUTHOR)

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.

Lang, Yitian¹ (AUTHOR), Lin, Yan¹ (AUTHOR), Deng, Meng¹ (AUTHOR), Liu, Xiaoyan¹ (AUTHOR) xiaoyan5156@163.com

Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Robbrecht, Debbie¹ (AUTHOR), Grob, Jean‐Jacques² (AUTHOR), Bechter, Oliver³ (AUTHOR), Simonelli, Matteo^4,5 (AUTHOR), Doger, Bernard⁶ (AUTHOR), Borbath, Ivan⁷ (AUTHOR), Butler, Marcus O.⁸ (AUTHOR), Cheng, Tina⁹ (AUTHOR), Romano, Patricia Martin¹⁰ (AUTHOR), Pons‐Tostivint, Elvire¹¹ (AUTHOR), Di Nicola, Massimo¹² (AUTHOR), Curigliano, Giuseppe^13,14 (AUTHOR), Ryu, Min‐Hee¹⁵ (AUTHOR), Rodriguez‐Vida, Alejo¹⁶ (AUTHOR), Schadendorf, Dirk^17,18,19,20 (AUTHOR), Garralda, Elena²¹ (AUTHOR), Abbadessa, Giovanni²² (AUTHOR), Demers, Brigitte²³ (AUTHOR), Amrate, Amele²³ (AUTHOR), Wang, Hong²⁴ (AUTHOR)

Fortgeschrittenes Plattenepithelkarzinom, das sich auf einer chronischen Hidradenitis suppurativa entwickelt hat und erfolgreich mit Cemiplimab behandelt wurde: ein Fallbericht.

Ruggiero, Angelo¹ (AUTHOR), Lauro, Wanda¹ (AUTHOR), Miano, Chiara¹ (AUTHOR), Villani, Alessia¹ (AUTHOR), Fabbrocini, Gabriella¹ (AUTHOR), Marasca, Claudio¹ (AUTHOR)

Excellent response to cemiplimab and radiotherapy in advanced metastatic porocarcinoma.

Abu Rached, Nessr¹ (AUTHOR) nessr.aburached@kklbo.de, Dervenis, Vasileios¹ (AUTHOR), Scheel, Christina¹ (AUTHOR), Stücker, Markus¹ (AUTHOR), Baues, Christian² (AUTHOR), Mauch, Cornelia¹ (AUTHOR), Doerler, Martin¹ (AUTHOR)

CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.

Park, Soo, Ellison, David, Weight, Ryan, Homsi, Jade, Rabinowits, Guilherme, Ruiz, Emily, Strasswimmer, John, Simmons, Josh, Panella, Timothy, Quek, Ruben, Pouliot, Jean-Francois, Khushalani, Nikhil

application/pdf

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.

Mallardo, Domenico¹ (AUTHOR), Simeone, Ester¹ (AUTHOR), Festino, Lucia¹ (AUTHOR), Tuffanelli, Marilena¹ (AUTHOR), Vanella, Vito¹ (AUTHOR), Trojaniello, Claudia¹ (AUTHOR), Vitale, Maria Grazia¹ (AUTHOR), Ottaviano, Margaret¹ (AUTHOR), Capone, Mariaelena¹ (AUTHOR), Madonna, Gabriele¹ (AUTHOR), Sparano, Francesca¹ (AUTHOR), Cioli, Eleonora¹ (AUTHOR), Scarpato, Luigi¹ (AUTHOR), Palla, Marco¹ (AUTHOR), Di Trolio, Rossella¹ (AUTHOR), Meinardi, Paolo¹ (AUTHOR), Caracò, Corrado¹ (AUTHOR), Ferrara, Gerardo¹ (AUTHOR), Muto, Paolo¹ (AUTHOR), Cavalcanti, Ernesta¹ (AUTHOR)

The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies.

Wang, Bi‐Cheng¹ (AUTHOR) bcsnowell@163.com, Xiao, Bo‐Ya^2,3 (AUTHOR), Kuang, Bo‐Hua¹ (AUTHOR), Lin, Guo‐He⁴ (AUTHOR)

Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.

Bailly-Caillé, Barbara¹ (AUTHOR), Levard, Romain¹ (AUTHOR) romain.levard@unicaen.fr, Kottler, Diane¹ (AUTHOR), Dompmartin, Anne¹ (AUTHOR), L'Orphelin, Jean-Matthieu^1,2 (AUTHOR) lorphelin-jm@chu-caen.fr

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.

Hasegawa, Kosei, Takahashi, Shunji, Ushijima, Kimio, Okadome, Masao, Yonemori, Kan, Yokota, Harushige, Vergote, Ignace, Monk, Bradley, Tewari, Krishnansu, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Paccaly, Anne, Takehara, Kazuhiro, Usami, Tomoka, Aoki, Yoichi, Suzuki, Nao, Kobayashi, Yoichi, Yoshida, Yoshio, Watari, Hidemichi, Seebach, Frank, Lowy, Israel, Mathias, Melissa, Fury, Matthew, Oaknin, Ana

application/pdf

Integration of immunotherapy and radiotherapy in a therapeutic algorithm for locally advanced squamous cell skin cancer

Koukourakis, Ioannis M., Karpouzis, Antonios, Filippatos, Konstantinos, Mamalis, Panagiotis, Kakagia, Despina, Giatromanolaki, Alexandra, Kouloulias, Vassilis, Zygogianni, Anna, Koukourakis, Michael I.^{Aff3, IDs12032025027853_cor1}

Eosinophil‐induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.

Lyu, Lu, Bian, Sainan, Guan, Kai, Zhao, Bin

Cemiplimab‐induced gingival hyperplasia.

Chen, Maggie¹ (AUTHOR) maggiechen@som.umaryland.edu, Jaenke Hill, Madison¹ (AUTHOR) madison.hill@som.umaryland.edu, Driscoll, Marcia¹ (AUTHOR) mdriscoll@som.umaryland.edu

Aggressive cutaneous squamous cell carcinoma in a patient on Janus-kinase inhibitor therapy

Ana M. Aragon Sierra, MD, Kevin J. Donohoe, MD, Daniel J. Canaday, MD, Ernest D. Gomez, MD, Scharukh M. Jalisi, MD, Matthew M. Koomey, MD, Victor M. Aviles, MD, Kenneth K. Yu, MD, PhD

electronic resource

Visa; Visa

Posterior Uveitis Associated with Cemiplimab.

Dow, Eliot R.¹ (AUTHOR), Hou, Kirk¹ (AUTHOR), Ransome, Susan¹ (AUTHOR), Abbassi, Sam² (AUTHOR), Tsui, Edmund¹ (AUTHOR) ETsui@mednet.ucla.edu

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy.

Lambert-Swainston, Chalette, Samlowski, Wolfram, Reynolds, Brandon, Hedayat, Amin

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

Michael S. Chang, MD, Jordan T. Said, MD, Elliot H. Akama-Garren, PhD, Nicole Trepanowski, MD, Ai-Tram N. Bui, MD, Anita Giobbie-Hurder, MS, Nicole R. LeBoeuf, MD, MPH, Rebecca I. Hartman, MD, MPH

electronic resource

Visa; Visa